09:04 AM EDT, 05/02/2024 (MT Newswires) -- Alnylam Pharmaceuticals ( ALNY ) reported a Q1 non-GAAP net loss Thursday of $0.16 per diluted share, narrowing from a loss of $1.06 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.63.

Revenue for the quarter ended March 31 was $494.3 million, up from $319.3 million a year earlier.

Analysts surveyed by Capital IQ expected $426.7 million.

The company said it continues to expect 2024 net product revenue from Onpattro, Amvuttra, Givlaari and Oxlumo of $1.40 billion to $1.50 billion. Net revenue from collaborations and royalties for the year is still expected to be between $325 million and $425 million, the company said.

Shares of the company were up 4% in recent Thursday premarket activity.

Price: 156.00, Change: +6.04, Percent Change: +4.03